Is Adeshwar Meditex overvalued or undervalued?

As of 29 October 2025, Adeshwar Meditex's valuation grade has moved from fair to expensive, indicating a shift in its perceived value. The company is currently overvalued, with a PE ratio of 14.15, an EV to EBITDA ratio of 8.91, and a PEG ratio of 4.74. These figures suggest that the stock may not justify its current price given its earnings growth prospects.
In comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 55.86, and Vimta Labs, which has a PE of 49.13. This indicates that while Adeshwar Meditex is considered expensive, it is still more attractively priced than some of its peers. Additionally, the stock has underperformed against the Sensex, particularly in the year-to-date period, where it has returned -21.92% compared to the Sensex's 8.78%.